Browse the toolkit beneath workflows. The mechanism branch runs mechanism -> architecture -> component, while the technique branch runs from high-level approaches down to concrete methods.
25 items matching 1 filter
Mechanism Branch
Layer 1
Mechanisms
Top-level concepts: biophysical action modes such as heterodimerization, photocleavage, or RNA binding.
Layer 2
Architectures
Arrangements that realize or deploy mechanisms, including switches, construct patterns, and delivery strategies.
Layer 3
Components
Low-level parts and sequence-defined elements used inside architectures, including protein domains and RNA elements.
Technique Branch
Layer 1
Approaches
High-level engineering practices such as computational design, directed evolution, sequence verification, and functional assay.
Layer 2
Methods
Concrete methods used to design, build, verify, or characterize engineered systems.
Showing 1-25 of 25
we engineered six-helix bundle DNA origami-CRISPR complexes that achieved nucleolin-targeted genome editing in cervical cancer cells, coupling GFP-based diagnostics with therapeutic E7 oncogene disruption
By using CRISPR-Cas9 technology, we inserted ARGs into the genome and optimized the promoter strength and copy number for ARG expression, constructing ultrasound-visible engineered bacteria expressing gas vesicles on the genome.
This review covers latest approaches, such as genome editing with CRISPR, targeting susceptibility genes
We present translational routes, sentinel epimarkers (bisulfite amplicons, CUT&Tag), haplotype-by-epigenotype prediction, and precise cis-regulatory editing to accelerate marker development, genomic prediction and the breeding of resilient soybean varieties with stable yields.
CRISPR-Cas-mediated genome editing is a programmable genome-editing approach discussed here in the context of bacterial systems. The cited review summarizes the main approaches for bacterial CRISPR-Cas editing and the difficulties associated with applying these systems in bacteria.
Engineered immune cells in this evidence context are immune cells rapidly modified using CRISPR-Cas9 for cancer immunotherapeutic applications. The supplied evidence supports CRISPR-Cas9-based generation of such cells but does not identify specific immune cell types, edited loci, or therapeutic payloads.
Ex vivo stem cell modification and re-transplantation is a clinical delivery workflow in which a patient's own stem cells are isolated, genetically modified outside the body with CRISPR-based approaches, and returned to the same patient. The supplied evidence identifies this format as common among current clinical CRISPR trials.
Gene editing technology is an engineering method used for animal model construction. The supplied evidence specifically states that it has been widely applied to nonhuman primate model generation in recent years.
Oncolytic viruses are described in this evidence set as viral platforms that can be rapidly engineered with CRISPR-Cas9 for cancer immunotherapeutic applications. The cited role is as an editable delivery harness within cancer therapy development.
CRISPR/Cas is a DNA manipulation and genome editing technology derived from a prokaryotic immune system. It recognizes and destroys invading genetic elements and has progressed from bench research toward clinical practice.
CRISPR/Cas9 mediated genome editing is a genome engineering method used in the cited 2016 Scientific Reports study to investigate the functional role of human Interleukin-8 gene haplotypes. The supplied evidence supports its application in editing a specific human gene-haplotype context.
Duplex CRISPR/Cas9 technology is a genome-editing method that uses two guide RNAs to target intronic sequences flanking an exon, enabling excision of the intervening exon by Cas9-mediated cleavage. In human U-2 OS osteosarcoma cells, it was applied to generate CRY1 knockout, CRY2 knockout, and CRY1/CRY2 double knockout cell models.
The supplied web research summary states that the anchor review names CRISPR-Combo as a system enabling simultaneous genome editing and gene activation in plants.
CRISPR/Cas9 is a genome editing technique used in the cited study to generate Cib1 and Cib2 knockout mice. In this evidence set, its demonstrated function is targeted gene disruption for mouse model production.
Precision genome editing can be achieved by using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) along with long-acting slow-effective release antiretroviral therapy.
Looking ahead, continued refinements in vector design, CRISPR-based editing strategies, and delivery platforms are expected to expand the therapeutic reach of gene therapy beyond monogenic disorders.
Future progress will require integrated multi-omics, fluxomics, and proximity-labeling approaches, combined with CRISPR-based isoform editing and promoter engineering.
Recent technological advances-such as clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (CRISPR/Cas9)-based cytokine pathway editing...are reshaping adoptive immunotherapy.
further genetic engineering through CRISPR/Cas9- and TALEN-based approaches for genome editing will pave the way for successful clinical applications
Advances in molecular genetics have led to the development of targeted treatments, including gene replacement therapy, RNA-based therapies, and CRISPR/Cas9 gene editing
Recent advances in synthetic biology, particularly the development of CRISPR-Cas genome editing technology, offer a revolutionary approach to designing Lactobacillus strains with customized traits... we reviewed the research progress of CRISPR-Cas9 gene editing in Lactobacillus... CRISPR-Cas9 toolkits are expected to achieve directed evolution of strain performance.
Countermeasures now integrate ... CRISPR/Cas9-validated receptor knockouts revealing functional redundancy
This review focuses on the fundamental technologies that have enabled such advances, which include DNA synthesis, programmable gene circuits, and CRISPR/Cas-based genome editing.
These findings make the spliceosome an attractive new target for small-molecule, antisense, and genome-editing therapeutic interventions.
further genetic engineering through CRISPR/Cas9- and TALEN-based approaches for genome editing will pave the way for successful clinical applications